Breaks Categories: News

WednesdayJul 26, 2017 9:55 am

NetworkNewsBreaks – Net Element’s (NASDAQ: NETE) PayOnline Announces Support for iDEAL

Global financial technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE), through its PayOnline subsidiary, this morning announced that it has added support for iDEAL (https://www.ideal.nl/en/), a popular e-commerce payment system and market share leader in the Netherlands. Per a report by Thuiswinkel.org and the Ecommerce Foundation, the iDEAL payment system is currently the most widely used method of online payments in the Netherlands, accounting for roughly 54 percent of all Dutch online payments across over 220 million transactions as of 2015. This market presence is particularly noteworthy as online spending in the Netherlands continues to grow. In 2016,…

Continue Reading

WednesdayJul 26, 2017 9:23 am

NetworkNewsBreaks – ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Issues Update on Construction and Expansion Activities

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning provided an update on its construction and expansion timelines for its Vanluven and Kimmett facilities, both of which are located in Napanee, Ontario. Per the update, ABcann’s plans to commence construction at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot Phase 1 project have been expanded to 100,000 square feet. Additionally, the company has initiated immediate expansion and construction efforts at its current production facility at Vanluven with the goal of doubling production capacity in order to…

Continue Reading

TuesdayJul 25, 2017 2:22 pm

NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Shares Plunge on Top-line Phase 2 Data of NSI-189 for MDD

Shares of Neuralstem (NASDAQ: CUR) plummeted 57% following the company’s release of top-line data from its exploratory phase 2 clinical trial on the efficacy of NSI-189 for Major Depressive Disorder (MDD). The trial did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS). The trial evaluated NSI-189 at 40 mg once daily and 40 mg twice daily compared to placebo. The 40 mg once daily dose was directionally positive on the MADRS. One of the trial's two secondary endpoints, the patient-rated Symptoms of Depression Questionnaire (SDQ), achieved statistical…

Continue Reading

TuesdayJul 25, 2017 12:02 pm

NetworkNewsBreaks – Flex Pharma, Inc.’s (NASDAQ: FLKS) FLX-787 Receives Fast Track Designation from FDA to Treat Severe ALS Cramps

Flex Pharma (NASDAQ: FLKS) shares are up 23% this morning on news that the company’s co-activator of TRPA1 and TRPV1, FLX-787, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to treat severe muscle cramps in patients with ALS. Currently, no treatments for this condition are approved in the U.S. “With Phase 2 clinical trials in both ALS and CMT expected to initiate this quarter in the US, FLX-787 will be amongst the most advanced, novel compounds in the clinic for these degenerative neurological diseases. The R&D team is focused on the execution of these…

Continue Reading

TuesdayJul 25, 2017 11:11 am

NetworkNewsBreaks – ORHub, Inc. (ORHB) Announces Launch of Neurosurgery Service Line

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) this morning announced the launch of its fourth service line, marking the company’s strategically planned entry point into neurosurgery. “We are excited to announce the new Neurosurgery service line so quickly after launching our previous modules,” Colt Melby, CEO of ORHub, stated in the news release. “The need for our software in the operating room is monumental, and we are aggressively working to expand our service line offerings to deliver our transformative software to key hospitals in major U.S. markets.” The company’s portfolio of service lines now includes software solutions for Spinal,…

Continue Reading

MondayJul 24, 2017 1:04 pm

NetworkNewsBreaks – Eltek (NASDAQ: ELTK) Shares Swell on $3M Order by Governmental Authority

Eltek (NASDAQ: ELTK) shares soared 79% toward its 52-week high of $1.33 this morning after the company said it has received an order of approximately $3 million from a governmental authority for a project comprising of manufacturing and procurement services. The project will take place during a period of two years measured by quarterly milestones the company is required to meet. At the end of the two years, the government authority will have the option to extend the project for an additional 12-month period. Eltek will receive quarterly payments subject to achieving the set milestones. "The selection of Eltek by…

Continue Reading

MondayJul 24, 2017 1:01 pm

NetworkNewsBreaks – Cytori Therapeutics, Inc. (NASDAQ: CYTX) Shares Plummet to New Low on Disappointing STAR Trial Results

Shares of Cytori Therapeutics (NASDAQ: CYTX) sunk to a new 52-week low of $0.45 following the company’s release of top-line preliminary data from its pivotal STAR trial of Habeo™ Cell Therapy in patients with scleroderma. Results show that statistical significance was not achieved in the primary endpoint, Cochin Hand Function Score (CHFS), or the secondary endpoint, Raynaud’s Condition Score. However, clinically meaningful efficacy trends were observed in both the efficacy endpoints. “We are disappointed that the study missed the primary and secondary endpoints. However, we are very encouraged by the trends toward improved hand function and scleroderma-related health status in…

Continue Reading

MondayJul 24, 2017 9:40 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Subsidiary Files Record of ‘CBD Magic Hemp Series’ Product Line Ahead of Impending Launch

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). These products, which comprise the new ‘CBD Magic Hemp Series’ skin care line, are expected to launch in late August and early September of this year, positioning CBD Biotechnology as a first-mover in an untapped segment of China’s skin care industry. “As one of the first skin care products containing CBD extract marketed in China, CBD Magic Hemp…

Continue Reading

MondayJul 24, 2017 9:11 am

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Enters Binding Letter of Intent to Purchase Cranbury International

Education technology company ProBility Media Corp. (OTCQB: PBYA) this morning announced that it has signed a binding letter of intent to purchase Cranbury International, an exporter of educational and reference materials located in Montpelier, Vermont. The acquisition is expected to close within 30 days and will significantly expand ProBility’s reach in markets throughout South and Central America, as well as the Caribbean. Cranbury, which markets and represents roughly 40 major publishers, currently sells educational materials to government institutions and private sector markets in Brazil, Mexico, Columbia, Trinidad and other international regions. “The purchase of Cranbury complements ProBility's international strategy of…

Continue Reading

FridayJul 21, 2017 12:35 pm

NetworkNewsBreaks – TearLab Corp. (NASDAQ: TEAR) Shares Skyrocket on Regulatory Approval of Commercial TearLab Discovery™ System in EU

TearLab (NASDAQ: TEAR) shares are up 84% mid-day following news that the company’s commercial version of its TearLab Discovery™ System has met all the applicable provisions of In Vitro Diagnostic Medical Devices Directive 98/79 EC required for CE Marking. Regulatory clearance enables the company the ability to market in the European Union and European Free Trade Association member countries and expands regulatory clearance beyond the previously-cleared discovery device to include the first commercial test card. The company is expected to use this clearance to build a clinical data package in support of a 510(k) submission to the FDA, which is…

Continue Reading